MOVALIS meloxicam 15 mg capsule blister pack

Ország: Ausztrália

Nyelv: angol

Forrás: Department of Health (Therapeutic Goods Administration)

Aktív összetevők:

meloxicam

Beszerezhető a:

Arrow Pharma Pty Ltd

INN (nemzetközi neve):

Meloxicam

Engedélyezési státusz:

Registered

Betegtájékoztató

MOVALIS
®
- Consumer Medicine Information
Page 1 of 5
MOVALIS
® CAPSULES
meloxicam
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about MOVALIS.
It does not contain all of the
available information. It does not
take the place of talking to your
doctor or pharmacist.
All medicines have benefits and
risks. Your doctor has weighed the
risks of you taking MOVALIS against
the benefits they expect it will have
for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO
YOUR DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH YOUR
MEDICINE. You may need to read
it again.
WHAT MOVALIS IS USED
FOR
MOVALIS is used to treat the
symptoms of osteoarthritis and
rheumatoid arthritis. Both diseases
mainly affect the joints causing pain
and swelling.
Although it can relieve symptoms
such as pain and inflammation, it
will not cure your condition.
MOVALIS belongs to a family of
medicines called Non-Steroidal Anti-
inflammatory Drugs (NSAIDs).
These medicines work by relieving
pain and inflammation.
It is available only with a doctor's
prescription.
Your doctor may have prescribed
MOVALIS for another reason. Ask
your doctor if you have any
questions about why MOVALIS has
been prescribed for you.
BEFORE YOU TAKE IT
When you must not take it
DO NOT TAKE MOVALIS IF YOU ARE
ALLERGIC TO:
•
MELOXICAM
•
ASPIRIN OR OTHER NSAIDS
•
ANY OF THE INGREDIENTS LISTED
AT THE END OF THIS LEAFLET (THIS
INCLUDES LACTOSE).
Some of the symptoms of an
allergic reaction may include skin
rash, itching or hives, swelling of
the face, lips, tongue or other parts
of the body, shortness of breath,
wheezing or troubled breathing.
DO NOT TAKE MOVALIS IF:
•
you are about to undergo
coronary artery bypass graft
surgery
•
you have a disease of the heart
with shortness of breath, and
swelling of the feet or lips due to
fluid build-up
•
you experience bleeding from the
stomach, gut or any other
bleeding
•
you have had a stroke resulting
from a bleed in the brain or you
have a bleeding disorder
•
yo

Termékjellemzők

MOVALIS CAPSULES- Product Information
Page 1 of 19
MOVALIS
® CAPSULES
(meloxicam)
PRODUCT INFORMATION
NAME OF THE MEDICINE
Active ingredient: meloxicam
Chemical names:
4-hydroxy-2-methyl-
N
-(5-methyl-2-thiazolyl)-2
H
-1,2-benzothiazine-
3-carboxamide-1,1-dioxide
and
2
H
-1,2-benzothiazine-3-carboxamide,4-hydroxy-2-
methy-
N
-(5-methyl-2-thiazolyl)-,1,1-dioxide.
Molecular formula: C
14
H
13
N
3
O
4
S
2
Molecular weight: 351.4
CAS number 71125-38-7
Structural formula:
DESCRIPTION
Meloxicam is a pastel yellow solid with pKa values of 1.09 and 4.18
and a melting point of
about 256
°
C. The substance is practically insoluble in water, soluble in
dimethylformamide,
slightly soluble in chloroform and acetone, and very slightly soluble
in methanol. There are
no chiral centres and no polymorphs are formed under normal
conditions. MOVALIS is
available as capsules. The list of excipients for the capsules is
provided below:
Capsules (7.5 mg and 15 mg): sodium citrate dihydrate, lactose
monohydrate, maize starch,
magnesium stearate, gelatin, indigo carmine CI73015, iron oxide yellow
CI77492, titanium
dioxide, purified water.
MOVALIS- Product Information
Page 2 of 19
PHARMACOLOGY
MOVALIS is a non-steroidal anti-inflammatory drug (NSAID) of the
enolic acid class, which
has shown anti-inflammatory, analgesic and antipyretic properties in
animals. Meloxicam
showed anti-inflammatory activity in all standard models of
inflammation. A common
mechanism for the above effects may exist in the ability of meloxicam
to inhibit the
biosynthesis
of
prostaglandins,
known
mediators
of
inflammation,
by
inhibition
of
cyclooxygenase (COX).
Comparison of the ulcerogenic dose and the anti-inflammatory effective
dose in rat adjuvant
arthritis model confirmed a greater therapeutic margin in animals over
other NSAIDs
(piroxicam, diclofenac, naproxen, flurbiprofen). In rats, meloxicam
showed greater inhibitory
effect on prostaglandin biosynthesis at the site of inflammation than
in the gastric mucosa or
the kidney.
Selective inhibition of the cyclo